Thrivent Financial for Lutherans increased its holdings in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 5.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,796 shares of the specialty pharmaceutical company’s stock after acquiring an additional 390 shares during the period. Thrivent Financial for Lutherans owned approximately 0.06% of ANI Pharmaceuticals worth $318,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. First Trust Advisors LP increased its stake in shares of ANI Pharmaceuticals by 1.2% during the first quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock valued at $1,067,000 after purchasing an additional 179 shares in the last quarter. Rhumbline Advisers grew its stake in shares of ANI Pharmaceuticals by 7.7% in the 4th quarter. Rhumbline Advisers now owns 30,954 shares of the specialty pharmaceutical company’s stock worth $1,909,000 after buying an additional 2,217 shares during the last quarter. Swiss National Bank increased its position in ANI Pharmaceuticals by 2.4% during the 4th quarter. Swiss National Bank now owns 17,400 shares of the specialty pharmaceutical company’s stock valued at $1,073,000 after buying an additional 400 shares in the last quarter. State Street Corp raised its stake in ANI Pharmaceuticals by 2.3% during the fourth quarter. State Street Corp now owns 309,863 shares of the specialty pharmaceutical company’s stock valued at $19,109,000 after buying an additional 7,029 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in ANI Pharmaceuticals by 78.0% in the fourth quarter. Victory Capital Management Inc. now owns 15,183 shares of the specialty pharmaceutical company’s stock worth $936,000 after acquiring an additional 6,652 shares in the last quarter. Institutional investors and hedge funds own 65.65% of the company’s stock.
NASDAQ ANIP opened at $32.34 on Wednesday. The stock has a market capitalization of $377.71 million, a price-to-earnings ratio of 7.48 and a beta of 1.45. ANI Pharmaceuticals Inc has a 1-year low of $28.28 and a 1-year high of $86.96. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.00 and a quick ratio of 1.33. The business’s fifty day moving average price is $31.32 and its 200-day moving average price is $46.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.15. The company had revenue of $49.77 million during the quarter, compared to analysts’ expectations of $49.40 million. ANI Pharmaceuticals had a positive return on equity of 23.92% and a negative net margin of 0.67%. Equities research analysts anticipate that ANI Pharmaceuticals Inc will post 3.74 EPS for the current year.
ANIP has been the subject of several recent analyst reports. Raymond James lowered their price target on ANI Pharmaceuticals from $65.00 to $49.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. BidaskClub raised shares of ANI Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Cantor Fitzgerald cut shares of ANI Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $78.00 to $40.00 in a report on Thursday, May 7th. TheStreet downgraded shares of ANI Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 8th. Finally, Guggenheim lowered their price objective on ANI Pharmaceuticals from $62.00 to $58.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. ANI Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $46.50.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: Return On Assets
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.